ADReCS

Pharmaceutical Information

Drug Name	Cefuroxime
Drug ID	BADD_D00407
Description	Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.
Indications and Usage	For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.
Marketing Status	approved
ATC Code	J01DC02; S01AA27
DrugBank ID	DB01112
KEGG ID	D00262
MeSH ID	D002444
PubChem ID	41375
TTD Drug ID	D0Y2IE
NDC Product Code	0143-9567; 0143-9569; 0143-9976; 0143-9568; 0143-9977; 0143-9979
UNII	O1R9FJ93ED
Synonyms	Cefuroxime \| Cephuroxime \| Zinacef \| Ketocef

Chemical Information

Molecular Formula	C16H16N4O8S
CAS Registry Number	55268-75-2
SMILES	CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Urticaria	23.04.02.001; 10.01.06.001	0.004779%
Uveitis	06.04.03.003; 10.02.01.023	0.000858%
Vaginal discharge	21.08.02.002	-	-
Vaginal infection	21.14.02.002; 11.01.10.002	-	-
Ventricular fibrillation	02.03.04.008	0.000143%
Vertigo	17.02.12.002; 04.04.01.003	-	-
Vision blurred	17.17.01.010; 06.02.06.007	-	-
Visual acuity reduced	06.02.10.012; 17.17.01.011	0.002575%
Visual field defect	06.02.07.003; 17.17.01.001	0.002089%		Not Available
Visual impairment	06.02.10.013	0.003935%		Not Available
Vitreous haemorrhage	24.07.05.005; 06.10.03.001	0.000286%
Vomiting	07.01.07.003	0.004865%
Vulvovaginal candidiasis	11.03.03.005; 21.14.02.003	-	-	Not Available
Vulvovaginal discomfort	21.08.02.005	-	-	Not Available
Wheezing	22.03.01.009	0.000773%
Yellow skin	23.03.03.042; 09.01.01.009; 08.01.03.046	0.000215%		Not Available
Tubulointerstitial nephritis	20.05.02.002	0.000429%		Not Available
Acute generalised exanthematous pustulosis	11.07.01.018; 10.01.01.034; 23.03.10.002; 12.03.01.005	0.001216%		Not Available
Retinal toxicity	06.09.03.013; 12.03.01.036	0.002790%		Not Available
Peripheral swelling	08.01.03.053; 02.05.04.015	-	-	Not Available
Red blood cell sedimentation rate increased	13.01.03.001	-	-	Not Available
General physical health deterioration	08.01.03.018	0.000787%		Not Available
Muscle tightness	15.05.03.007	-	-	Not Available
Neonatal hypoxia	22.11.02.002; 18.04.15.002	0.000143%		Not Available
Dyschezia	07.02.03.005	0.000143%		Not Available
Necrotising colitis	07.08.01.013	0.000215%		Not Available
Conjunctival hyperaemia	06.04.01.004	0.000143%		Not Available
Haemodynamic instability	24.03.02.006	0.000215%		Not Available
Lymphatic disorder	01.09.01.003	-	-	Not Available
Musculoskeletal stiffness	15.03.05.027	-	-	Not Available

The 10th Page First Pre 10 11 12 13 Next Last Total 13 Pages